

## Consumer Healthcare turnover

Three months ended 30 June 2015

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
Wellness	740	>100	>100
Oral health	462	11	6
Nutrition	165	7	9
Skin health	142	>100	95
Total	1,509	51	48

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
US	360	66	81
Europe	470	90	74
International	679	27	23
Total	1,509	51	48

## Consumer Healthcare turnover

Six months ended 30 June 2015

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
Wellness	1,333	75	73
Oral health	947	10	6
Nutrition	347	4	8
Skin health	263	70	65
Total	2,890	37	35

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
US	690	56	71
Europe	834	60	46
International	1,366	19	17
Total	2,890	37	35

**Pharmaceuticals and Vaccines turnover – Three months ended 30 June 2015**

	Total			US			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<b>Respiratory</b>	<b>1,467</b>	<b>(6)</b>	<b>(6)</b>	<b>704</b>	<b>(12)</b>	<b>(4)</b>	<b>369</b>	<b>(8)</b>	<b>(16)</b>	<b>394</b>	<b>5</b>	<b>2</b>
<i>Anoro Ellipta</i>	15	>100	>100	12	>100	>100	3	-	-	-	-	-
<i>Avamys/Veramyst</i>	59	9	2	7	(14)	-	22	-	(4)	30	21	7
<i>Flixotide/Flovent</i>	159	(10)	(8)	100	(15)	(7)	22	8	(8)	37	(8)	(8)
<i>Relvar/Breo Ellipta</i>	53	>100	>100	19	>100	>100	19	>100	>100	15	>100	>100
<i>Seretide/Advair</i>	960	(13)	(12)	484	(17)	(9)	267	(16)	(23)	209	-	(3)
<i>Ventolin</i>	160	2	3	81	3	11	28	-	(7)	51	2	(4)
Other	61	5	5	1	-	-	8	(11)	(11)	52	4	6
<b>Cardiovascular, metabolic and urology (CVMU)</b>	<b>242</b>	<b>5</b>	<b>4</b>	<b>102</b>	<b>2</b>	<b>12</b>	<b>66</b>	<b>4</b>	<b>(7)</b>	<b>74</b>	<b>10</b>	<b>4</b>
<i>Avodart</i>	192	(2)	(4)	66	(9)	(1)	66	6	(6)	60	(2)	(5)
Other	50	45	52	36	33	50	-	(100)	(100)	14	100	75
<b>Immuno-inflammation</b>	<b>56</b>	<b>27</b>	<b>37</b>	<b>51</b>	<b>21</b>	<b>34</b>	<b>3</b>	<b>33</b>	<b>-</b>	<b>2</b>	<b>-</b>	<b>-</b>
<i>Benlysta</i>	56	30	40	51	21	34	3	33	-	2	>100	>100
Other	-	(100)	(100)	-	-	-	-	-	-	-	(100)	(100)
<b>Oncology</b>	<b>19</b>	<b>(94)</b>	<b>(94)</b>	<b>(2)</b>	<b>&lt;(100)</b>	<b>&lt;(100)</b>	<b>(1)</b>	<b>(100)</b>	<b>&lt;(100)</b>	<b>22</b>	<b>(71)</b>	<b>(68)</b>
<b>Other pharmaceuticals</b>	<b>542</b>	<b>(6)</b>	<b>(9)</b>	<b>61</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>138</b>	<b>(7)</b>	<b>(14)</b>	<b>343</b>	<b>(13)</b>	<b>(15)</b>
Dermatology	105	(8)	(10)	10	(9)	(9)	34	(12)	(19)	61	(5)	(5)
<i>Augmentin</i>	143	2	(2)	-	-	-	37	(5)	(14)	106	4	2
Other anti-bacterials	42	(19)	(22)	2	-	-	12	-	(8)	28	(26)	(28)
Rare diseases	94	2	(4)	11	22	22	30	(3)	(12)	53	2	(4)
Other	158	(11)	(12)	38	>100	>100	25	(14)	(14)	95	(30)	(34)
<b>Innovative Pharmaceuticals</b>	<b>2,326</b>	<b>(14)</b>	<b>(14)</b>	<b>916</b>	<b>(16)</b>	<b>(9)</b>	<b>575</b>	<b>(19)</b>	<b>(26)</b>	<b>835</b>	<b>(7)</b>	<b>(10)</b>
<b>Established products</b>	<b>655</b>	<b>(5)</b>	<b>(6)</b>	<b>168</b>	<b>(16)</b>	<b>(9)</b>	<b>121</b>	<b>(13)</b>	<b>(20)</b>	<b>366</b>	<b>3</b>	<b>1</b>
<i>Coreg</i>	29	(10)	(3)	29	(10)	(3)	-	-	-	-	-	-
<i>Hepsera</i>	18	(14)	(14)	-	-	-	-	-	-	18	(14)	(14)
<i>Imigran/Imitrex</i>	46	7	5	27	23	23	13	(7)	(13)	6	(14)	(14)
<i>Lamictal</i>	132	6	6	67	2	12	23	-	(12)	42	16	11
<i>Lovaza</i>	24	(22)	(11)	24	(22)	(11)	-	-	-	-	-	-
<i>Requip</i>	23	(12)	(12)	-	(100)	(100)	7	(36)	(36)	16	14	14
<i>Serevent</i>	24	(8)	(8)	11	11	22	9	(23)	(31)	4	-	-
<i>Seroxat/Paxil</i>	43	(6)	(12)	(7)	-	-	9	-	(10)	41	8	5
<i>Valtrex</i>	46	30	24	6	(38)	(25)	7	(13)	(13)	33	71	57
<i>Zeffix</i>	33	(23)	(18)	1	-	-	1	-	(50)	31	(24)	(16)
Other	237	(11)	(13)	10	(65)	(62)	52	(15)	(21)	175	(1)	(3)
<b>Global Pharmaceuticals</b>	<b>2,981</b>	<b>(12)</b>	<b>(13)</b>	<b>1,084</b>	<b>(16)</b>	<b>(9)</b>	<b>696</b>	<b>(18)</b>	<b>(25)</b>	<b>1,201</b>	<b>(4)</b>	<b>(7)</b>
<b>HIV</b>	<b>559</b>	<b>59</b>	<b>59</b>	<b>308</b>	<b>84</b>	<b>&gt;100</b>	<b>172</b>	<b>46</b>	<b>32</b>	<b>79</b>	<b>26</b>	<b>15</b>
<i>Combivir</i>	9	(44)	(44)	3	(1)	8	2	(44)	(49)	4	(56)	(56)
<i>Epzicom/Kivexa</i>	185	1	(2)	67	(10)	(2)	80	4	(6)	38	17	10
<i>Lexiva/Agenerase</i>	18	(10)	(14)	10	(23)	(16)	3	(27)	(35)	5	53	16
<i>Selzentry</i>	31	(18)	(18)	15	(3)	6	13	(6)	(15)	3	(67)	(65)
<i>Tivicay</i>	145	>100	>100	95	83	100	37	>100	>100	13	>100	>100
<i>Triumeq</i>	149	-	-	109	-	-	31	-	-	9	-	-
<i>Trizivir</i>	7	-	-	2	>100	>100	4	(23)	(31)	1	5	50
Other	15	(11)	(17)	7	14	-	2	(50)	-	6	(22)	(33)
<b>Pharmaceuticals</b>	<b>3,540</b>	<b>(6)</b>	<b>(6)</b>	<b>1,392</b>	<b>(5)</b>	<b>3</b>	<b>868</b>	<b>(10)</b>	<b>(18)</b>	<b>1,280</b>	<b>(3)</b>	<b>(6)</b>
<b>Vaccines</b>	<b>814</b>	<b>11</b>	<b>7</b>	<b>240</b>	<b>13</b>	<b>24</b>	<b>274</b>	<b>27</b>	<b>16</b>	<b>300</b>	<b>(2)</b>	<b>(9)</b>
<i>Bexsero</i>	30	-	-	2	-	-	24	-	-	4	-	-
<i>Boostrix</i>	96	3	3	52	9	21	31	31	19	13	(38)	(46)
<i>Cervarix</i>	18	(14)	(14)	1	-	-	9	-	(10)	8	(30)	(20)
<i>Fluarix, FluLaval</i>	7	29	-	(4)	<(100)	<(100)	-	-	-	11	83	83
Hepatitis	121	(15)	(15)	58	(7)	2	37	(15)	(21)	26	(29)	(32)
<i>Infanrix, Pediarix</i>	187	(4)	(7)	64	(12)	(4)	81	(3)	(13)	42	7	-
<i>Menveo</i>	43	-	-	25	-	-	7	-	-	11	-	-
<i>Rabipur/Rabivert</i>	15	-	-	5	-	-	6	-	-	4	-	-
<i>Rotarix</i>	101	2	(1)	30	17	25	15	7	-	56	(5)	(11)
<i>Synflorix</i>	77	(20)	(27)	-	-	-	8	-	(11)	69	(22)	(29)
Other	119	48	38	7	-	-	56	63	47	56	29	17
	<b>4,354</b>	<b>(3)</b>	<b>(4)</b>	<b>1,632</b>	<b>(3)</b>	<b>6</b>	<b>1,142</b>	<b>(3)</b>	<b>(12)</b>	<b>1,580</b>	<b>(3)</b>	<b>(6)</b>

**Pharmaceuticals and Vaccines turnover – Six months ended 30 June 2015**

	Total			US			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<b>Respiratory</b>	<b>2,875</b>	<b>(8)</b>	<b>(7)</b>	<b>1,287</b>	<b>(16)</b>	<b>(9)</b>	<b>761</b>	<b>(6)</b>	<b>(13)</b>	<b>827</b>	<b>5</b>	<b>2</b>
<i>Anoro Ellipta</i>	27	>100	>100	21	>100	>100	5	-	-	1	-	-
<i>Avamys/Veramyst</i>	130	8	2	13	(20)	(13)	39	2	(5)	78	17	8
<i>Flixotide/Flovent</i>	312	(16)	(15)	183	(27)	(21)	49	2	(9)	80	4	1
<i>Relvar/Breo Ellipta</i>	94	>100	>100	33	>100	>100	35	>100	>100	26	>100	>100
<i>Seretide/Advair</i>	1,858	(14)	(13)	876	(19)	(12)	558	(14)	(20)	424	(2)	(4)
<i>Ventolin</i>	321	(4)	(2)	159	(12)	(4)	60	3	(3)	102	6	2
Other	133	5	1	2	-	-	15	(6)	(6)	116	4	-
<b>Cardiovascular, metabolic and urology (CVMU)</b>	<b>460</b>	<b>(2)</b>	<b>(3)</b>	<b>185</b>	<b>(3)</b>	<b>6</b>	<b>134</b>	<b>(3)</b>	<b>(12)</b>	<b>141</b>	<b>1</b>	<b>(5)</b>
<i>Avodart</i>	371	(4)	(7)	122	(11)	(3)	132	4	(6)	117	(7)	(11)
Other	89	12	17	63	19	31	2	(91)	(82)	24	59	41
<b>Immuno-inflammation</b>	<b>116</b>	<b>23</b>	<b>32</b>	<b>106</b>	<b>21</b>	<b>33</b>	<b>7</b>	<b>33</b>	<b>17</b>	<b>3</b>	<b>50</b>	<b>50</b>
<i>Benlysta</i>	107	27	35	97	24	35	7	33	17	3	>100	>100
Other	9	(11)	-	9	-	13	-	-	-	-	(100)	(100)
<b>Oncology</b>	<b>235</b>	<b>(58)</b>	<b>(58)</b>	<b>91</b>	<b>(63)</b>	<b>(60)</b>	<b>69</b>	<b>(62)</b>	<b>(66)</b>	<b>75</b>	<b>(40)</b>	<b>(40)</b>
<b>Other pharmaceuticals</b>	<b>1,067</b>	<b>(7)</b>	<b>(10)</b>	<b>103</b>	<b>29</b>	<b>37</b>	<b>287</b>	<b>(3)</b>	<b>(12)</b>	<b>677</b>	<b>(12)</b>	<b>(14)</b>
Dermatology	214	(10)	(11)	22	(13)	(8)	71	(8)	(15)	121	(10)	(9)
<i>Augmentin</i>	283	(1)	(5)	-	-	-	88	(4)	(13)	195	1	(2)
Other anti-bacterials	89	(17)	(20)	3	-	-	28	(9)	(18)	58	(22)	(22)
Rare diseases	185	(4)	(10)	23	(33)	(30)	62	1	(7)	100	1	(5)
Other	296	(10)	(11)	55	>100	>100	38	5	(3)	203	(26)	(27)
<b>Innovative Pharmaceuticals</b>	<b>4,753</b>	<b>(12)</b>	<b>(12)</b>	<b>1,772</b>	<b>(17)</b>	<b>(10)</b>	<b>1,258</b>	<b>(12)</b>	<b>(19)</b>	<b>1,723</b>	<b>(5)</b>	<b>(8)</b>
<b>Established products</b>	<b>1,305</b>	<b>(13)</b>	<b>(14)</b>	<b>331</b>	<b>(31)</b>	<b>(25)</b>	<b>253</b>	<b>(14)</b>	<b>(20)</b>	<b>721</b>	<b>(3)</b>	<b>(4)</b>
<i>Coreg</i>	56	(16)	(10)	56	(16)	(10)	-	-	-	-	-	-
<i>Hepsera</i>	40	(11)	(9)	-	-	-	-	-	-	40	(11)	(9)
<i>Imigran/Imitrex</i>	84	(4)	(7)	45	(4)	(2)	26	(7)	(13)	13	-	(7)
<i>Lamictal</i>	259	2	4	130	1	11	46	(6)	(15)	83	9	5
<i>Lovaza</i>	52	(64)	(61)	52	(64)	(61)	-	-	-	-	-	-
<i>Requip</i>	45	(13)	(17)	1	(75)	(75)	14	(27)	(36)	30	7	7
<i>Serevent</i>	47	(11)	(11)	21	6	17	19	(23)	(27)	7	(11)	(22)
<i>Seroxat/Paxil</i>	86	(13)	(17)	(7)	-	-	17	(18)	(23)	76	(4)	(7)
<i>Valtrex</i>	88	24	19	11	(29)	(21)	13	(13)	(13)	64	53	42
<i>Zeffix</i>	72	(19)	(15)	1	(50)	(50)	3	-	(25)	68	(19)	(14)
Other	476	(14)	(15)	21	(60)	(55)	115	(14)	(21)	340	(8)	(8)
<b>Global Pharmaceuticals</b>	<b>6,058</b>	<b>(12)</b>	<b>(12)</b>	<b>2,103</b>	<b>(20)</b>	<b>(13)</b>	<b>1,511</b>	<b>(12)</b>	<b>(20)</b>	<b>2,444</b>	<b>(5)</b>	<b>(7)</b>
<b>HIV</b>	<b>1,005</b>	<b>51</b>	<b>52</b>	<b>537</b>	<b>76</b>	<b>92</b>	<b>326</b>	<b>40</b>	<b>28</b>	<b>142</b>	<b>18</b>	<b>11</b>
<i>Combivir</i>	19	(41)	(41)	6	(9)	(1)	5	(48)	(53)	8	(47)	(47)
<i>Epzicom/Kivexa</i>	361	1	(1)	127	(10)	(1)	162	6	(3)	72	10	4
<i>Lexiva/Agenerase</i>	34	(19)	(21)	20	(21)	(14)	7	(32)	(38)	7	4	(19)
<i>Selzentry</i>	61	(14)	(14)	29	(1)	8	25	(9)	(17)	7	(50)	(49)
<i>Tivicay</i>	257	>100	>100	167	>100	>100	66	>100	>100	24	>100	>100
<i>Triumeq</i>	230	-	-	171	-	-	49	-	-	10	-	-
<i>Trizivir</i>	14	(22)	(22)	4	(6)	2	8	(27)	(34)	2	(26)	1
Other	29	(23)	(26)	13	(19)	(19)	4	(38)	(50)	12	(20)	(20)
<b>Pharmaceuticals</b>	<b>7,063</b>	<b>(7)</b>	<b>(7)</b>	<b>2,640</b>	<b>(10)</b>	<b>(2)</b>	<b>1,837</b>	<b>(6)</b>	<b>(14)</b>	<b>2,586</b>	<b>(4)</b>	<b>(6)</b>
<b>Vaccines</b>	<b>1,513</b>	<b>11</b>	<b>7</b>	<b>457</b>	<b>14</b>	<b>24</b>	<b>498</b>	<b>15</b>	<b>5</b>	<b>558</b>	<b>5</b>	<b>(2)</b>
<i>Bexsero</i>	37	-	-	2	-	-	30	-	-	5	-	-
<i>Bostrix</i>	162	5	5	89	11	22	48	29	17	25	(33)	(38)
<i>Cervarix</i>	46	(14)	(18)	2	-	-	19	(16)	(24)	25	(14)	(14)
<i>Fluarix, FluLaval</i>	11	(20)	(27)	(1)	<(100)	<(100)	-	-	100	12	(7)	(14)
Hepatitis	264	(1)	1	122	12	21	78	(10)	(16)	64	(7)	(6)
<i>Infanrix, Pediarix</i>	373	(5)	(8)	133	(12)	(4)	158	(6)	(15)	82	10	3
<i>Menveo</i>	54	-	-	32	-	-	8	-	-	14	-	-
<i>Rabipur/Rabivert</i>	20	-	-	8	-	-	7	-	-	5	-	-
<i>Rotarix</i>	199	7	5	62	14	24	32	3	(3)	105	6	(1)
<i>Synflorix</i>	137	(10)	(18)	-	-	-	17	(10)	(19)	120	(10)	(18)
Other	210	40	29	8	>100	>100	101	47	33	101	29	17
	<b>8,576</b>	<b>(4)</b>	<b>(5)</b>	<b>3,097</b>	<b>(7)</b>	<b>1</b>	<b>2,335</b>	<b>(2)</b>	<b>(10)</b>	<b>3,144</b>	<b>(2)</b>	<b>(5)</b>